Varecle 1mg (Varenicline Tartrate)

Adult dose

Patients should set a quit date and start taking this medicine 1 week before that date. Alternatively, they may begin quitting smoking between days 8 and 35 after starting this medicine. Take this medicine after a meal with plenty of water. Days 1–3: 0.5 mg once daily Days 4–7: 0.5 mg twice daily Day 8 through the end of treatment: 1 mg twice daily For patients who cannot tolerate the adverse reactions to this medicine, the dose may be reduced temporarily or on an ongoing basis. Treatment with this medicine lasts 12 weeks. For patients who successfully quit smoking with the initial 12 weeks of treatment, an additional 12 weeks of treatment with this medicine is recommended to increase the likelihood of long-term abstinence. For patients who are unable or unwilling to stop smoking abruptly, gradual smoking cessation while taking this medicine may be considered. Within the first 4 weeks after starting treatment, smoking should be reduced by 50% compared with the amount smoked before treatment began, and by an additional 50% within the next 4 weeks. Smoking should continue to be reduced so that complete abstinence is achieved by 12 weeks. Take this medicine for an additional 12 weeks for a total treatment period of 24 weeks. No dose adjustment is necessary in patients with mild (estimated creatinine clearance > 50 mL/min and ≤ 80 mL/min) to moderate (estimated creatinine clearance ≥ 30 mL/min and ≤ 50 mL/min) renal impairment. In patients with severe renal impairment (estimated creatinine clearance < 30 mL/min), the recommended starting dose of varenicline is 0.5 mg once daily. If needed, the maximum dose is 0.5 mg twice daily. In patients with end-stage renal disease receiving hemodialysis, if well tolerated, a maximum dose of 0.5 mg once daily may be administered. No dose adjustment is necessary in patients with hepatic impairment. In elderly patients, renal function is more likely to be reduced, so caution should be exercised when selecting the dose, and monitoring renal function may be useful.

Child dose

Under 18 years of age: administration is not recommended.

This medication is used to aid in smoking cessation. Serious mental health issues such as depression, suicidal thoughts, aggressive behavior, and hallucinations may occur during treatment, so careful observation is necessary. Individuals with a history of psychiatric disorders should cautiously use this medication after consulting their physician. Women who are pregnant or breastfeeding should consult a doctor before using this medication. Side effects such as nausea, headaches, insomnia, abnormal dreams, and anxiety can commonly occur during treatment. Any unusual symptoms should be reported to a physician immediately, and the medication should be discontinued. Dangerous activities such as driving or operating machinery should be performed cautiously after taking this medication. Because this medication is excreted through the kidneys, elderly patients or those with impaired kidney function may require dose adjustment. In case of an overdose, immediate medical attention should be sought. Interactions with other medications are not significant, but alcohol consumption should be minimized or avoided. Use in children is not recommended as safety and efficacy have not been established. This medication can cause physical and mental changes related to smoking cessation, so it is important to closely follow a physician's instructions before and during treatment.

• Suicidal thoughts
• suicidal behavior
• suicide
• changes in behavior or thoughts
• depression
• mania
• mood changes
• psychosis
• aggressive behavior
• hallucinations

This medication is susceptible to air and moisture; therefore, it should be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 to 30 degrees Celsius. This will help safely preserve the medication's effectiveness.

Appearance

Light blue, bi-convex, rectangular film-coated tablets

Package unit

28 tablets (14 tablets/blister x 2)